Abstract
The signal transduction of tumor necrosis factor-alpha (TNF-alpha) is complex and regulated via a vast number of interconnecting pathways. The TNF-alpha signaling pathway plays a major role in the pathogenesis of subarachnoid hemorrhage (SAH). The advent of molecular mimicry has provided a number of opportunities to tackle disease with improved specificity. Here we review the mechanisms of their action and the potential for TNF-alpha inhibitors as a treatment for subarachnoid hemorrhage. Searches were performed using PubMed with the search terms "subarachnoid haemorrhage", "TNF alpha", "novel drugs" TNF alpha inhibition", "management", "cerebral aneurysm", and "vasospasm' from 1970 to February, 2012. Articles were also identified through searches of the Cochrane library and searches of the authors’ own files. Only papers published in English were reviewed. In conclusion, there is considerable theoretical evidence for the potential of TNF-alpha inhibitors to impact on the pathogenesis of aneurismal SAH. Such indications demonstrate the potential for specific targeting of molecular signaling pathways to prevent the growth and rupture of cerebral aneurysm.
Keywords: TNF, aneurysm, SAH, inflammation
Current Drug Safety
Title:Specific TNF-alpha Inhibition in Cerebral Aneurysm formation and Subarachnoid Hemorrhage
Volume: 7 Issue: 3
Author(s): Adam M.H. Young, Surya K.Karri, Wanchun You and Christopher S. Ogilvy
Affiliation:
Keywords: TNF, aneurysm, SAH, inflammation
Abstract: The signal transduction of tumor necrosis factor-alpha (TNF-alpha) is complex and regulated via a vast number of interconnecting pathways. The TNF-alpha signaling pathway plays a major role in the pathogenesis of subarachnoid hemorrhage (SAH). The advent of molecular mimicry has provided a number of opportunities to tackle disease with improved specificity. Here we review the mechanisms of their action and the potential for TNF-alpha inhibitors as a treatment for subarachnoid hemorrhage. Searches were performed using PubMed with the search terms "subarachnoid haemorrhage", "TNF alpha", "novel drugs" TNF alpha inhibition", "management", "cerebral aneurysm", and "vasospasm' from 1970 to February, 2012. Articles were also identified through searches of the Cochrane library and searches of the authors’ own files. Only papers published in English were reviewed. In conclusion, there is considerable theoretical evidence for the potential of TNF-alpha inhibitors to impact on the pathogenesis of aneurismal SAH. Such indications demonstrate the potential for specific targeting of molecular signaling pathways to prevent the growth and rupture of cerebral aneurysm.
Export Options
About this article
Cite this article as:
M.H. Young Adam, K.Karri Surya, You Wanchun and S. Ogilvy Christopher, Specific TNF-alpha Inhibition in Cerebral Aneurysm formation and Subarachnoid Hemorrhage, Current Drug Safety 2012; 7 (3) . https://dx.doi.org/10.2174/157488612803251315
DOI https://dx.doi.org/10.2174/157488612803251315 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design A Giant Internal Iliac Artery Aneurysm with Arteriovenous Fistulization
Current Medical Imaging Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Trends in Nanotechnology Patents Applied to the Health Sector
Recent Patents on Nanotechnology Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry Microbleeds after Stent-assisted Coil Embolization of Unruptured Intracranial Aneurysms: Incidence, Risk Factors and the Role of Thromboelastography
Current Neurovascular Research Cervicocranial Arterial Dissection: An Analysis of the Clinical Features, Prognosis, and Treatment Efficacy
Current Neurovascular Research Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Genetic Determinants of Cerebral Arterial Adaptation to Flow-loading
Current Neurovascular Research Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research